20 April 2022 
EMA/226690/2022  
Human Medicines Evaluation Division 
Statement  indicating compliance with the agreed 
completed paediatric investigation plan 
Medicinal  product  
Halaven/ eribulin 
See Annex A  
Pharmaceutical form(s): 
See Annex A 
Strength(s): 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
See Annex A 
Number(s) in the Community 
Register of Medicinal Products: 
Marketing  authorisation holder (MAH): 
Name and address of the  MAH:  Eisai GmbH 
Edmund-Rumpler-Strasse 3 
60549  Frankfurt am Main 
GERMANY 
Procedure  
Procedure number: 
EMEA/H/C/002084/IB/0063 
Further to  the compliance check performed under Article 23 of  Regulation (EC) No 1901/2006,  and in 
accordance with Article 28(3)  and Article 45(3)  of the  said Regulation it  is concluded that:  
- the development of this  product has complied with  all measures in the  agreed paediatric investigation 
plan P/0535/2021  for the Soft Tissue Sarcoma with  the full compliance check procedure EMEA -C-
001261-PIP01-11-M07.  All studies in the agreed paediatric investigation plan P/00535/2021  were 
conducted after the  entry into  force of that Regulation,     
- the Summary of Product Characteristics adopted by CHMP  already reflected the results of studies 
conducted in compliance with  this  agreed paediatric investigation plan.  
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
